In this free White Paper, we are going to walk step-by-step through:
The ONE type of pharmacoeconomic analysis you cannot do without when evaluating new drugs
This type of analysis lets you directly compare all of the costs and health benefits of drugs used to treat different disease states, so you can consistently and transparently judge the value of all drugs you are considering for formulary listing.
The critical importance of selecting the correct comparator drug for every pharmacoeconomic analysis
If you don’t get this right, you could end up with a highly skewed cost-effectiveness estimate that could lead to listing a drug on your formulary that does not improve the health of your plan members or provide value for money.
How to make direct comparisons between drugs for disparate disease states
How do you make consistent decisions when you’re evaluating drugs for disease states as disparate as rheumatoid arthritis and epilepsy? Discover the true comparison you need to look for.